Product Images Tadalafil
View Photos of Packaging, Labels & Appearance
- Label - 71610 0908 39
- Aphena - Aphena
- f35596a7-figure-01 - f35596a7 figure 01
- f35596a7-figure-02 - f35596a7 figure 02
- f35596a7-figure-03 - f35596a7 figure 03
- f35596a7-figure-04 - f35596a7 figure 04
- f35596a7-figure-05 - f35596a7 figure 05
- f35596a7-figure-06 - f35596a7 figure 06
- f35596a7-figure-07 - f35596a7 figure 07
- f35596a7-figure-08 - f35596a7 figure 08
- f35596a7-figure-09 - f35596a7 figure 09
Product Label Images
The following 11 images provide visual information about the product associated with Tadalafil NDC 71610-908 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - 71610 0908 39
Aphena - Aphena
f35596a7-figure-01 - f35596a7 figure 01
f35596a7-figure-02 - f35596a7 figure 02
This text appears to be describing blood pressure measurements of both diastolic and systolic values in standing and supine positions over time. The readings for Diastolic BP and Systolic BP are given separately for standing and supine positions at different hours. These measurements can be useful for monitoring changes in blood pressure under different postures and through time.*
f35596a7-figure-03 - f35596a7 figure 03
This text appears to show a graph or chart representing the "Standing Systolic BP (Blood Pressure) (mmHg)" levels over some time or treatment. The graph seems to include data points related to "Tadalafil 20 mg & doxazosin 8 mg" at different time intervals. The information presented may be related to the effects of this combination medication on blood pressure.*
f35596a7-figure-04 - f35596a7 figure 04
This document appears to be a record of Systolic Blood Pressure readings taken at different time points following the administration of different medications (20 mg tadalafil and 8 mg doxazosin). The readings were taken at 08:00 and 20:00. The text presents a comparison between the effects of tadalafil and doxazosin in terms of their impact on blood pressure.*
f35596a7-figure-05 - f35596a7 figure 05
f35596a7-figure-06 - f35596a7 figure 06
This text provides information on the IPSS Total Score change from baseline over the duration of treatment with Tadalafil tablets 5 mg compared to a placebo. The graph shows a statistically significant difference (p<0.001) between the two groups over a 12-week treatment period.*
f35596a7-figure-07 - f35596a7 figure 07
This is a comparison between Tadalafil tablets of 5 mg and a placebo over a duration of treatment in weeks. The results indicate statistical significance with p<0.001.*
f35596a7-figure-08 - f35596a7 figure 08
LS Mean Change from Baseline for TadalafilFinasteride and PlaceboFinasteride treatment groups. The analysis includes the Least Squares Treatment Difference between the two groups.*
f35596a7-figure-09 - f35596a7 figure 09
This text provides information about a study involving Tadalafil tablets at a dose of 5 mg compared to a placebo. The statistical significance is indicated with p<0.01. The outcome of the study is likely related to the duration of treatment in weeks, shown in the graph with time points ranging from 0 to 12 weeks.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
